2025-06Studienarbeit
Incidence and prevalence of NET and NEC in Germany: a retrospective cancer registry analysis
Ipsen Pharma GmbH
Little is known about the current incidence and prevalence of neuroendocrine tumors (NET) and neuroendicrone carcinomas (NEC) in Germany, especially for lung-NET. Reported data is outdated or based on extrapolations, partly from other countries. No comprehensive epidemiology, especially on lung-NET is available for Germany.
To close this gap, we plan to use data from the German center for cancer registry (Zentrum für Krebsregisterdaten, ZfKD) based on Landeskrebsregister, an extensive sample of newly diagnosed cancer cases in Germany to estimate incidence and prevalence. This study will establish the incidence rates and prevalence of NET and NEC in Germany and furthermore establish the epidemiology in histological subgroups of the respective patients including lung-NET.
Primary Study Objectives: To estimate the annual incidence rate of NET in Germany in 2019, 2020, 2021, 2022 and 2023
Referenzen
Is Referenced By: E-Poster: "A cancer registry analysis of neuroendocrine neoplasms in Germany." Präsentiert von Prof. Sebastian Krug, Ipsen Pharma GmbH im Rahmen der 23. Jahrestagung der European Neuroendocrine Tumor Society (ENETS) 2026.
Keine Lizenzangabe
